Eligibility for lecanemab treatment in a French memory clinic setting - PubMed
5 hours ago
- #Alzheimer's disease
- #Memory clinic
- #Lecanemab
- Study assesses eligibility for lecanemab treatment in a French memory clinic setting.
- Anti-amyloid monoclonal antibodies like lecanemab and donanemab are now available for Alzheimer's disease (AD) treatment.
- Retrospective observational study of 3075 patients, with 676 undergoing CSF testing and 356 having biomarker-confirmed AD.
- Using CLARITY AD trial criteria, 28.6% (90 patients) were eligible; French AURs reduced eligibility to 23.8% (75 patients).
- Low MMSE scores and MRI findings were common exclusion criteria.
- Eligibility rates from the entire source population were 2.9% (CLARITY AD) and 2.4% (French AURs).
- At follow-up, 34.5% of initially eligible patients no longer met MMSE criteria.
- Study highlights limited eligibility in specialized settings and the need for early AD diagnosis and efficient screening.